Alan T. Chang

798 total citations
18 papers, 383 citations indexed

About

Alan T. Chang is a scholar working on Rheumatology, Surgery and Physiology. According to data from OpenAlex, Alan T. Chang has authored 18 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 7 papers in Surgery and 6 papers in Physiology. Recurrent topics in Alan T. Chang's work include Mast cells and histamine (6 papers), Eosinophilic Esophagitis (6 papers) and Eosinophilic Disorders and Syndromes (6 papers). Alan T. Chang is often cited by papers focused on Mast cells and histamine (6 papers), Eosinophilic Esophagitis (6 papers) and Eosinophilic Disorders and Syndromes (6 papers). Alan T. Chang collaborates with scholars based in United States, Germany and Austria. Alan T. Chang's co-authors include Bradford A. Youngblood, Jeremy A. O’Sullivan, Bruce S. Bochner, Bhupinder Singh, Henrik Rasmussen, Richard B. Crook, Sabine Altrichter, Christopher Bebbington, Nenad Tomas̆ević and Frank Siebenhaar and has published in prestigious journals such as Blood, Gastroenterology and Biochemical Journal.

In The Last Decade

Alan T. Chang

18 papers receiving 381 citations

Peers

Alan T. Chang
Anton Żawrocki Poland
Ashley M. Mahler United States
Carlos Cerveró Spain
Floris van Alphen Netherlands
Sara Andreone Italy
Wenhan Du China
Jison Hong United States
Saloua Zrioual France
Irene Low New Zealand
Thomas Guerrier France
Anton Żawrocki Poland
Alan T. Chang
Citations per year, relative to Alan T. Chang Alan T. Chang (= 1×) peers Anton Żawrocki

Countries citing papers authored by Alan T. Chang

Since Specialization
Citations

This map shows the geographic impact of Alan T. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan T. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan T. Chang more than expected).

Fields of papers citing papers by Alan T. Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan T. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan T. Chang. The network helps show where Alan T. Chang may publish in the future.

Co-authorship network of co-authors of Alan T. Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Alan T. Chang. A scholar is included among the top collaborators of Alan T. Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan T. Chang. Alan T. Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Siebenhaar, Frank, Sabine Altrichter, Hanna Bonnekoh, et al.. (2023). Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial. British Journal of Dermatology. 189(5). 511–519. 17 indexed citations
2.
Dellon, Evan S., Enoch Bortey, Alan T. Chang, et al.. (2023). Determination of Optimal Eosinophil Thresholds for Diagnosis of Eosinophilic Gastritis and Duodenitis: A Pooled Analysis of 4 Prospective Studies. Clinical and Translational Gastroenterology. 15(1). e00656–e00656. 8 indexed citations
3.
Bochner, Bruce S., Jeremy A. O’Sullivan, Alan T. Chang, & Bradford A. Youngblood. (2022). Siglecs in allergy and asthma. Molecular Aspects of Medicine. 90. 101104–101104. 16 indexed citations
4.
Tauber, Joseph, Quan Dong Nguyen, Peter Y. Chang, et al.. (2022). Lirentelimab for severe and chronic forms of allergic conjunctivitis. Journal of Allergy and Clinical Immunology. 150(3). 631–639. 28 indexed citations
5.
Dellon, Evan S., Mirna Chehade, Robert M. Genta, et al.. (2022). S449 Lirentelimab (AK002) Safety and Efficacy in Patients With Higher Eosinophil Thresholds: Supplementary Analysis of Phase 2/3 EoE KRYPTOS Trial. The American Journal of Gastroenterology. 117(10S). e318–e319. 1 indexed citations
6.
Dellon, Evan S., Mirna Chehade, Robert M. Genta, et al.. (2022). S446 Results from KRYPTOS, a Phase 2/3 Study of Lirentelimab (AK002) in Adults and Adolescents With EoE. The American Journal of Gastroenterology. 117(10S). e316–e317. 29 indexed citations
7.
Dellon, Evan S., Enoch Bortey, Alan T. Chang, et al.. (2022). Su1168: DETERMINATION OF OPTIMAL EOSINOPHIL THRESHOLDS FOR DIAGNOSIS OF EOSINOPHILIC GASTRITIS AND DUODENITIS: A POOLED ANALYSIS OF 4 PROSPECTIVE ADULT STUDIES. Gastroenterology. 162(7). S–527. 2 indexed citations
8.
Altrichter, Sabine, Petra Staubach, Bhupinder Singh, et al.. (2021). An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. Journal of Allergy and Clinical Immunology. 149(5). 1683–1690.e7. 76 indexed citations
9.
Dellon, Evan S., Nirmala Gonsalves, Marc E. Rothenberg, et al.. (2021). Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. Clinical Gastroenterology and Hepatology. 20(3). 535–545.e15. 33 indexed citations
10.
Peterson, Kathryn A., Mirna Chehade, Joseph A. Murray, et al.. (2021). 539 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8. Gastroenterology. 160(6). S–111. 1 indexed citations
11.
Youngblood, Bradford A., John Leung, Rustom Falahati, et al.. (2020). Discovery, Function, and Therapeutic Targeting of Siglec-8. Cells. 10(1). 19–19. 62 indexed citations
12.
O’Sullivan, Jeremy A., Alan T. Chang, Bradford A. Youngblood, & Bruce S. Bochner. (2020). Eosinophil and mast cell Siglecs: From biology to drug target. Journal of Leukocyte Biology. 108(1). 73–81. 53 indexed citations
13.
Dellon, Evan S., Kathryn A. Peterson, Joseph A. Murray, et al.. (2020). 932 HISTOLOGIC AND SYMPTOMATIC IMPROVEMENT ACROSS MULTIPLE FORMS OF EOSINOPHILIC GASTROINTESTINAL DISEASES IN ENIGMA, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ANTOLIMAB (AK002). Gastroenterology. 158(6). S–186. 3 indexed citations
14.
Youngblood, Bradford A., Emily C. Brock, John Leung, et al.. (2018). AK002, a Novel Humanized Monoclonal Antibody to Siglec-8, Inhibits Mast Cell Activity and Depletes Eosinophils in Ex Vivo Bone Marrow Tissue from Patients with Systemic Mastocytosis. Blood. 132(Supplement 1). 1104–1104. 4 indexed citations
15.
Rasmussen, Henrik, Alan T. Chang, Nenad Tomas̆ević, & Christopher Bebbington. (2018). A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Phase 1 Study of AK002, a Novel Siglec-8 Selective Monoclonal Antibody, in Healthy Subjects. Journal of Allergy and Clinical Immunology. 141(2). AB403–AB403. 20 indexed citations
16.
Lehman, Norman L., Alan T. Chang, & Richard B. Crook. (1998). Non-Lysosomal Cycling Pathway for Atrial Natriuretic Peptide Activated by Protein Kinase C in Human NPE Cells. Experimental Eye Research. 67(5). 549–559. 2 indexed citations
17.
Crook, Richard B. & Alan T. Chang. (1997). Differential regulation of natriuretic peptide receptors on ciliary body epithelial cells. Biochemical Journal. 324(1). 49–55. 19 indexed citations
18.
Chang, Alan T., Jon R. Polansky, & Richard B. Crook. (1996). Natriuretic peptide receptors on human trabecular meshwork cells. Current Eye Research. 15(2). 137–143. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anton Żawrocki Breakdown of academic impact, for papers by Ashley M. Mahler Breakdown of academic impact, for papers by Carlos Cerveró Breakdown of academic impact, for papers by Floris van Alphen Breakdown of academic impact, for papers by Sara Andreone Breakdown of academic impact, for papers by Wenhan Du Breakdown of academic impact, for papers by Jison Hong Breakdown of academic impact, for papers by Saloua Zrioual Breakdown of academic impact, for papers by Irene Low Breakdown of academic impact, for papers by Thomas Guerrier
Rankless by CCL
2026